Alireza Eghtedar

Statistics

Publications

Citations

329

H-Index

Active since

2011

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Colorado Blood Cancer Institute

Memorial Sloan Kettering Cancer Center

Sarah Cannon

Cleveland Clinic

Alireza Eghtedar is an author at The University of Texas MD Anderson Cancer Center specializing in hematologic malignancy therapy, medicine, and acute leukemias.

Publications per year

2011–2025

Publications

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Alireza Eghtedar, Srđan Verstovšek, Zeev Estrov et al. · Blood · 2012 · 200 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Joshua F. Zeidner, Junichiro Yuda, Justin M. Watts et al. · Blood · 2024 · 39 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia

Alireza Eghtedar, Hagop M. Kantarjian, Elias Jabbour et al. · Clinical Lymphoma Myeloma & Leukemia · 2013 · 27 citations · Full text

Medicine, Hematology, Oncology +10

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-<i>trans</i>retinoic acid plus chemotherapy or with all-<i>trans</i>retinoic acid plus arsenic trioxide

Alireza Eghtedar, I. Rodríguez, Hagop M. Kantarjian et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2014 · 26 citations

Medicine, Oncology, Pharmacology +14

Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia

Alireza Eghtedar, Gautam Borthakur, Farhad Ravandi et al. · American Journal of Hematology · 2011 · 15 citations · Full text

Medicine, Hematology, Oncology +17

1–5 of 7